Lurasidone and Cognition in Bipolar I Disorder

Sponsor

University of British Columbia (Other)

Overall Status

Completed

CT.gov ID

NCT02147379

Collaborator

(none)

Enrollment

Location

Arms

32.4

Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a 6 week, randomized, open-label, parallel group study in patients with Bipolar-I disorder (manic depression), who are in remission from an episode. Participants who show cognitive impairment at baseline will be randomized to receive open-label Lurasidone added on to their current medication(s) or continue their usual treatment for 6 weeks. Participants will have 3 clinical visits and 2 telephone appointments during the study. Given the preliminary evidence for efficacy of Lurasidone in improving cognition in schizophrenia, we propose to examine the efficacy of Lurasidone in improving cognition in bipolar patients.

Condition or Disease	Intervention/Treatment	Phase
Bipolar I Disorder	Drug: Lurasidone	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

53 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Changes in Cognitive Functioning in Euthymic Bipolar Patients Treated With Lurasidone Versus Treatment as Usual; A Randomized, Open-Label Study.

Study Start Date :

May 1, 2014

Actual Primary Completion Date :

Oct 1, 2015

Actual Study Completion Date :

Jan 12, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lurasidone Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.	Drug: Lurasidone Other Names: Latuda
No Intervention: Treatment as usual Patients randomized to this arm will continue their usual treatment.

Arm

Intervention/Treatment

Experimental: Lurasidone

Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.

Drug: Lurasidone

Other Names:

Latuda

No Intervention: Treatment as usual

Patients randomized to this arm will continue their usual treatment.

Outcome Measures

Primary Outcome Measures

Cognitive Change in Bipolar I disorder after treatment with Lurasidone [6 weeks]
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC) will be administered to assess cognitive functioning at baseline and at endpoint ( change in scores on cognitive tests) to evaluate the efficacy of lurasidone on cognitive changes in bipolar disorder.

Eligibility Criteria

Criteria

Ages Eligible for Study:

19 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All patients must be taking either lithium or valproate or one of the atypical antipsychotics for mood stabilization.
Patients who show cognitive impairments (-0.25 standard deviations (SD) or below) on either the Trail Making Test- trial B (TMT-B) or California Verbal Learning Test (CVLT) trials 1 to 5, or CVLT long delay free recall, at baseline visit.
Males or females aged 19 to 65 years inclusive.
Diagnostic and Statistical Manual IV edition (DSM-IV TR) diagnosis of Bipolar Type I Disorder, with or without a history of psychosis.
Clinically stable with a Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) score less than or equal to 8.
A sufficient level of English using a language screening questionnaire.
Capability of understanding, consenting to, and complying with the requirements of the study.

Exclusion Criteria:

A history of unstable or inadequately treated medical illnesses, including moderate to severe brain injury, or neurological illnesses impacting cognitive function.
Treatment with Electroconvulsive Therapy (ECT) within eight weeks prior to enrolment; or treatment with an experimental drug within 30 days prior to enrolment.
Axis I diagnosis of substance abuse or dependence within the past month.
Significant risk of harm to self or others, in the opinion of the investigator.
Pregnancy or lactation in female subjects.
Liver function tests (AST and ALT) three times the upper limit of normal. -